Terrestrial Bio

Terrestrial Bio’s lead program focuses on GLP-1s for obesity and metabolic disease, with the Tacterra patch delivering semaglutide comparably to subcutaneous injection.

The Tacterra platform delivers medicine through a patch applied painlessly with an applicator, dissolving bioactive tips into the skin for rapid therapeutic release.

Vaxess reported results from the completion of a Phase 1 trial for its Mimix-Flu vaccine patch.

Vaxess will collaborate with AstraZeneca to evaluate its patch delivery technology for an RNA-based pandemic influenza vaccine prototype.

Vaxess announced an additional $10 million in funding.

Vaxess shared interim results from a Phase 1 clinical trial of its Mimix-Flu vaccine patch.

The company focuses on advancing biomedical innovation.

John leads device development at Vaxess, with over 25 years of experience in medical device product development, including roles at SynAgile Corporation, Neograft Technologies, and Sonitus Medical.

Jon leads research and development at Vaxess, specializing in silk technologies for medical implants and drug delivery devices, with experience at Tufts University and the University of Pennsylvania.

Kathryn co-founded Vaxess after working as a postdoctoral research fellow at Harvard and in research and development at Merck. She earned a BA in chemistry from Colby College and a PhD in Physical Chemistry from Northwestern University.

Matthew serves as Vaxess Director of Engineering, bringing expertise in polymer-based microfabrication and medical device development from lab prototypes to commercial products.

The company engineers more effective and accessible vaccines and therapeutics using novel technology.

The company aims to engineer more effective and accessible vaccines and therapeutics through novel technology.

Contact Terrestrial

Contact Terrestrial

Terrestrial is transforming the delivery of next-generation therapies, starting with GLP-1. Terrestrial's proprietary microarray patch (MAP) and applicator platform, designed for self-administration, enables precise, controlled delivery of a wide range of therapeutics without medical sharps or refrigeration.

Terrestrial is transforming the delivery of next-generation therapies, starting with GLP-1. Terrestrial's proprietary microarray patch (MAP) and applicator platform, designed for self-administration, enables precise, controlled delivery of a wide range of therapeutics without medical sharps or refrigeration.

Terrestrial is developing delivery platforms for next-generation therapies, starting with GLP-1. Its microarray patch and applicator platform is designed for self-administration and enables precise, controlled delivery without medical sharps or refrigeration.

Terrestrial Bio’s privacy policy describes how it collects, uses, discloses, and otherwise processes personal information through its websites, mobile applications, and online services.

Terrestrial Bio has dosed the first patients in a **Phase 1 clinical trial** testing its **Tacterra™ Microarray Patch (MAP)** for delivering **semaglutide**, a diabetes and obesity treatment. The patch-based system aims to provide an alternative to injectable or oral administration methods. The trial marks a key step in evaluating the safety and efficacy of this transdermal drug delivery technology.

Jul 2026TerrestrialNews article

Terrestrial Bio showcases research on its **needle-free microarray patch (MAP)** at the **American Diabetes Association (ADA) 2026 conference**. The patch delivers an **amylin analog and GLP-1 therapy** without requiring coformulation, addressing potential formulation challenges in diabetes treatment. Early data highlights the patch’s potential as an alternative to traditional injection methods.

Jun 2026TerrestrialNews article

Terrestrial secures **$2.2 million in Massachusetts state grants** to expand production of its **Tacterra™ Microarray Patch**, a medical device. The funding supports scaling manufacturing capacity under the **Massachusetts Advanced Manufacturing Program (MAP)**. The company develops wearable biosensors for continuous health monitoring.

Jun 2026TerrestrialNews article

Terrestrial Bio (formerly Vaxess Technologies) secures **$50 million in Series C funding** to advance its **GLP-1 peptide delivery patch**, a non-injectable alternative for weight management and metabolic disorders. The rebrand positions the company as a developer of **transdermal drug delivery solutions**, targeting chronic disease treatments beyond obesity.

Mar 2026Drug Delivery BusinessNews article